English | 简体中文 | 繁體中文 | 한국어
Share:
Weifa ASA: Invitation to presentation of Weifa's Q1 2017 results, Thursday 27 April

Oslo, 21 April 2017

Weifa ASA (OSE: WEIFA), Norway's leading consumer health company, will release its first quarter 2017 results on Thursday 27 April 2017.

The results will be presented by Weifa's CEO Kathrine Gamborg Andreassen and CFO Simen Nyberg-Hansen at 08:30 CET at Felix Konferansesenter, Bryggetorget 3, Oslo, Norway. Following the presentation, there will be a Q&A session. The presentation will be held in English.

The presentation will also be webcast live and can be accessed directly from http://webtv.hegnar.no/presentation.php?webcastId=51528850or http://www.weifa.no/webcast.Questions may be submitted live during the presentation.

The quarterly report and the presentation materials will be available on www.weifa.com/Investor/ and www.newsweb.no, as well as on news wires.

Weifa welcomes all interested parties.

For further information, please contact:

Simen Nyberg-Hansen
CFO
+47 9820 6355
simen.nyberg-hansen@weifa.no

Weifa is Norway's leading consumer health company. We supply real value through medicines, lifestyle products and solutions that address the essential needs of consumers, customers and professional partners. Weifa was founded in 1940 and now employs about 30 highly qualified people at our headquarters in Oslo. The company has a strong position in Norway and is the market leader in pain relief, with well-established brands such as Paracet and Ibux. We are also present in other key areas such as dietary supplements and treatment for colds and respiratory problems. Weifa is listed on the Oslo Børs (ticker WEIFA). For further information, please visit: www.weifa.no




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Weifa ASA via Globenewswire

Copyright © Thomson Reuters 2018. All rights reserved.
Press Releases
Orion to sell its Orion Diagnostica division - Due to the transaction Orion updates its outlook  
Apr 21, 2018 00:30 ET
Helsinn Group announces the FDA approval of the IV formulation of AKYNZEO® (fosnetupitant/ palonosetron) in the United States  
Apr 20, 2018 21:33 ET
BOURBON: Positive progress in negotiations with lenders  
Apr 20, 2018 18:30 ET
Hubbell Incorporated Declares Regular Quarterly Dividend  
Apr 20, 2018 16:01 ET
Helsinn Group announces the FDA approval of the IV formulation of AKYNZEO® (fosnetupitant/ palonosetron) in the United States  
Apr 20, 2018 15:23 ET
Heineken Holding N.V. - Amendments to the Articles of Association  
Apr 20, 2018 15:18 ET
Lubrizol Presents Estane® TPU and Other Innovations for Consumer, Industrial, Footwear and Electronics Applications at Chinaplas 2018  
Apr 20, 2018 12:03 ET
Lipotec Active Ingredients Becomes Umbrella Brand  
Apr 19, 2018 23:43 ET
LEH PHARMA LTD.: Company Update  
Apr 18, 2018 19:34 ET
Tusk Therapeutics presents data on to its anti-CD25 programme at AACR Annual Meeting 2018  
Apr 18, 2018 19:33 ET
More News >>
Copyright © 2018 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 5791 1818

Connect With us: